# Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol

Study · id `cardio:ct-nct07255820` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07255820](<https://clinicaltrials.gov/study/NCT07255820>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07255820

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.

## Technical summary

Registry record NCT07255820. Randomized; no masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2026-03-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 126 participants (enrolled count; ClinicalTrials.gov record NCT07255820, source copy `cardio:ctgov-nct07255820-2026-10-20`, retrieved 2026-10-26)
- Started: 2026-01-01 (actual) (ClinicalTrials.gov record NCT07255820, source copy `cardio:ctgov-nct07255820-2026-10-20`, retrieved 2026-10-26)
- Primary completion: 2026-03-30 (actual) (ClinicalTrials.gov record NCT07255820, source copy `cardio:ctgov-nct07255820-2026-10-20`, retrieved 2026-10-26)
- Completion: 2026-06-30 (actual) (ClinicalTrials.gov record NCT07255820, source copy `cardio:ctgov-nct07255820-2026-10-20`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT07255820, source copy `cardio:ctgov-nct07255820-2026-10-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07255820-2026-10-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
- Condition: Type 2 Diabetes Mellitus
- Condition: Hypercholesterolemia / Elevated LDL Cholesterol
- Intervention (Drug): Rosuvastatin + Ezetimibe
- Intervention (Drug): Bempedoic Acid + Ezetimibe
- Intervention (Drug): Rosuvastatin + Ezetimibe + Bempedoic Acid
- Lead sponsor: Bahria University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Bahria University (`cardio:org-bahria-university`)

## Provenance

Content hash: 97882f5701bcab64d9407c41f2d9a8cd898a0dfb77f2a3ff4d3ce7c73d165689
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
